NCT04839341 is a Phase 1 clinical trial of Uproleselan in Relapsed/Refractory AML, sponsored by Apollomics Inc..

Who is sponsoring NCT04839341?

NCT04839341 is sponsored by Apollomics Inc..

What drugs are being tested in NCT04839341?

Interventions in NCT04839341: Uproleselan.

What condition does NCT04839341 study?

NCT04839341 studies Relapsed/Refractory AML.

Is NCT04839341 still recruiting?

NCT04839341 is currently completed. Last updated 27 June 2025.

Last reviewed 2025-06-27 · How we verify

NCT04839341

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients

Completed Phase 1 Last updated 27 June 2025

What this trial tests

Phase 1 trial testing Uproleselan in Relapsed/Refractory AML in 12 participants. Completed in 28 June 2024.

Timeline

24 February 2021

Primary endpoint
28 June 2024

28 June 2024

Quick facts

Lead sponsor	Apollomics Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	24 February 2021
Primary completion	28 June 2024
Estimated completion	28 June 2024
Sites	2 locations across China

Drugs / interventions tested

Uproleselan — full drug profile →

Conditions studied

Relapsed/Refractory AML — all drugs for Relapsed/Refractory AML →

Sponsor

Apollomics Inc. — full company profile →

Who can join

Adults 18 to 60, any sex, with Relapsed/Refractory AML. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the safety and tolerability of uproleselan(GMI-1271), a specific E-selectin antagonist, and characterize the pharmacokinetic (PK) profile of uproleselan, in combination with chemotherapy to treat Chinese relapsed/refractory AML patients.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Recent advances in targeted therapies in acute myeloid leukemia.
Bhansali RS, Pratz KW, Lai C. · · 2023 · cited 151× · PMID 36966300 · DOI 10.1186/s13045-023-01424-6
Remodeling of the bone marrow microenvironment during acute myeloid leukemia progression.
Urs AP, Goda C, Kulkarni R. · · 2024 · cited 11× · PMID 39118939 · DOI 10.21037/atm-23-1824
Aberrant glycosylation in hematologic malignancies: mechanisms, immune evasion, and therapeutic targeting.
Lu X, Song Z, Wang C, Pan B, et al · · 2026 · PMID 41963305 · DOI 10.1038/s41408-026-01493-z

Verify or expand the search:

Other trials of Uproleselan

Trials testing the same drug.

NCT05146739 — Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Mye · Phase 1 · active not recruiting
NCT05569512 — Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML · Phase 1 · terminated
NCT05054543 — Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML · Phase 3 · terminated
NCT05057221 — Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia · Phase 1, PHASE2 · terminated
NCT04964505 — Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia · Phase 1 · terminated

Other Apollomics Inc. trials

Trials by the same sponsor.

NCT05054543 — Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML · Phase 3 · terminated
NCT05055518 — APL-102 Capsule in Patients With Advanced Solid Tumors · Phase 1 · suspended
NCT03175224 — APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04839341 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Apollomics Inc.
Last refreshed: 27 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04839341.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing